仁和药业：2025年前三季度净利润约3.79亿元

Group 1 - The core viewpoint of the article highlights the financial performance of Renhe Pharmaceutical for the third quarter of 2023, indicating a decline in revenue and net profit compared to the previous year [1] Group 2 - For the first three quarters of 2023, Renhe Pharmaceutical reported revenue of approximately 2.833 billion yuan, a year-on-year decrease of 10.07% [1] - The net profit attributable to shareholders of the listed company was about 379 million yuan, reflecting a year-on-year decrease of 8.79% [1] - The basic earnings per share stood at 0.2708 yuan, also down by 8.79% year-on-year [1] - As of the report date, the market capitalization of Renhe Pharmaceutical was 8.6 billion yuan [2]